Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Breast Neoplasms 8Stomach Neoplasms 7Lung Neoplasms 7Small Cell Lung Carcinoma 5Rectal Neoplasms 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Esophageal Squamous Cell Carcinoma 4Recurrence 3NSCLC 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Muscle-invasive Bladder Cancer 2Multiple Myeloma 2Mesothelioma, Malignant 2Limited Stage Small Cell Lung Cancer 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Urologic Neoplasms 1Upper Tract Urothelial Carcinoma 1Thymus Neoplasms 1Sleep Initiation and Maintenance Disorders 1Resectable Non-small Cell Lung Cancer 1Pathologic Complete Response 1

Interventions

ribociclib 1exemestane 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Letrozole 1Drug Therapy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Anatomic Stage II Breast Cancer AJCC v8 × Drug Therapy × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡